Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 4/26/24 → 4/26/27 |
Financiación
- DalCor Pharmaceuticals Canada Incorporated: 45.789,00 US$
DAL-302 (dal-GenE-2) Trial: A Phase 3, Double-Blind, Randomized Placebo Controlled Study To Evaluate The Effects Of Dalcetrapib On CV Risk In A Genetically Defined Population With Recent ACS
- Kotter, John (PI)